Role of C-reactive protein as a biomarker for prediction of the severity of pulmonary exacerbations in patients with cystic fibrosis

BMC Pulmonary Medicine

Julio Ancochea¹  Gilda Fernandes-Vasconcelos¹  Rosa Mar Gómez-Punter¹  Carolina Cisneros¹  Claudia Valenzuela¹  Sara Yamamoto¹  José L Justicia³  Rosa Maria Girón-Moreno² 

[1] Pulmonology Department, la Princesa Institute for Health Research (IP). Hospital Universitario de la Princesa, Madrid, Spain;Pulmonology Department, Hospital Universitario de la Princesa, Diego de León, n° 62, Madrid 28006, Spain;Medical Affairs Department, Gilead Sciences, Madrid, Spain

关键词: Severity index;    Allergic bronchopulmonary aspergillosis;    Corticosteroids;    Pseudomonas aeruginosa;    Hospital admission;    Respiratory exacerbation;    Cystic fibrosis;    CRP;   

Others  :  1109525
DOI  :  10.1186/1471-2466-14-150

 received in 2014-05-26, accepted in 2014-09-10,  发布年份 2014

【 摘 要 】

Background

Pulmonary exacerbation is one of the main risk factors for death in patients with cystic fibrosis. Several biomarkers have proven useful in the diagnosis and treatment of pulmonary exacerbations, although none has been associated with severity. The objective of the present study was to investigate whether C-reactive protein (CRP) level was associated with the severity of pulmonary exacerbation requiring admission to hospital in patients with cystic fibrosis.

Methods

We designed a severity index for exacerbations based on 4 clinical parameters and determined whether there was an association between CRP levels and severity of the exacerbation. We also investigated the association between CRP and baseline functional and clinical variables.

Results

Twenty-seven patients with cystic fibrosis required 62 admissions to hospital. CRP levels were not significantly associated with the severity index, although they were associated with specific patient characteristics: colonization by Pseudomonas aeruginosa, allergic bronchopulmonary aspergillosis, treatment with oral corticosteroids, and number of severe exacerbations treated with intravenous antibiotics during the previous year.

Conclusions

CRP level is not associated with the severity of pulmonary exacerbations, but it is associated with specific clinical characteristics. This simple scoring system (severity index) could prove very useful for evaluating the severity of exacerbations.

【 授权许可】

   
2014 Girón-Moreno et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Salcedo Posadas A, Gartner S, Girón Moreno RM, García Novo MD: (Eds): Tratado de Fibrosis Quística. Madrid: Editorial Justim SL; 2012.
• [2]Mayer-Hamblett N, Rosenfeld M, Emerson J, Goss CH, Aitken ML: Developingcystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. Am J Respir Crit Care Med 2002, 166:1550-1555.
• [3]Amadori A, Antonelli A, Balteri I, Schreiber A, Bugiani M, De Rose V: Recurrent exacerbations affect FEV(1) decline in adult patients with cystic fibrosis. Respir Med 2009, 103:407-413.
• [4]de Boer K, Vandemheen KL, Tullis E, Doucette S, Fergusson D, Freitag A, Paterson N, Jackson M, Lougheed MD, Kumar V, Aaron SD: Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. Thorax. 2011, 66:680-5.
• [5]Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME: Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med. 1994, 331:637-42.
• [6]Dakin C, Henry RL, Field P, Morton J: Defining an exacerbation of pulmonary disease in cystic fibrosis. Pediatr Pulmonol 2001, 31:436-442.
• [7]Goss CH, Burns JL: Exacerbations in cystic fibrosis-1: epidemiology and pathogenesis. Thorax 2007, 62(4):360-367.
• [8]Smyth A: Update on treatment of pulmonary exacerbations in cystic fibrosis. Curr Opin Pulm Med 2006, 12:440-444.
• [9]Bell SC, Robinson PJ: Exacerbations in cystic fibrosis: 2. prevention. Thorax 2007, 62:723-732.
• [10]Smyth A, Elborn JS: Exacerbations in cystic fibrosis: 3. management. Thorax 2008, 63:180-184.
• [11]Rosenfeld M, Emerson J, Williams-Warren J, Pepe M, Smith A, Montgomery AB, Ramsey B: Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr. 2001, 139:359-65.
• [12]Cystic Fibrosis Foundation Patient Registry: Annual Data Report Bethesda, Maryland ©2013. Cystic Fibrosis: Foundation; 2012.
• [13]Ferkol T, Rosenfeld M, Milla CE: Cystic fibrosis pulmonary exacerbations. J Pediatr 2006, 148(2):259-264.
• [14]Bilton D, Canny G, Conway S, Dumcius S, Hjelte L, Proesmans M, Tümmler B, Vavrova V, De Boeck K: Pulmonary exacerbation: towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials. J Cyst Fibros. 2011, 10 Suppl 2:S79-81.
• [15]Flume PA, Mogayzel PJ Jr, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, Marshall BC: Clinical Practice Guidelines for Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009, 180(9):802-808.
• [16]Hakimi Shoki A, Mayer-Hamblett N, Wilcox P, Sin D, Quon B: Systematic review of blood biomarkers in cystic fibrosis pulmonary exacerbations. Chest 2013, 144(5):1659-1670.
• [17]Roderfeld M, Rath T, Schulz R, Seeger W, Tschuschner A, Graf J, Roeb E: Serum matrix metalloproteinases in adult CF patients: Relation to pulmonary exacerbation. J Cyst Fibros 2009, 8(5):338-47.
• [18]Davidson SJ, Paramothayan S, Hodson ME: Adult cystic fibrosis patients with and without infective exacerbations and their factor XII levels. Blood Coagul Fibrinolysis 2009, 20(6):400-402.
• [19]Hendry J, Elborn JS, Nixon L, Shale DJ, Webb AK: Cystic fibrosis: inflammatory response to infection with Burkholderia cepacia and Pseudomonas aeruginosa. Eur Respir J 1999, 14(2):435-438.
• [20]Rayner RJ, Wiseman MS, Cordon SM, Norman D, Hiller EJ, Shale DJ: Inflammatory markers in cystic fibrosis. Respir Med 1991, 85(2):139-145.
• [21]Eichler I, Nilsson M, Rath R, Enander I, Venge P, Koller DY: Human neutrophil lipocalin, a highly specific marker for acute exacerbation in cystic fibrosis. Eur Respir J 1999, 14(5):1145-1149.
• [22]Watkin SL, Elborn JS, Cordon SM, Hiller EJ, Shale DJ: C-reactive protein is not a useful indicator of intermittent bacterial colonization in early lung disease of patients with cystic fibrosis. Pediatr Pulmonol 1994, 17(1):6-10.
• [23]Peckham D, Crouch S, Humphreys H, Lobo B, Tse A, Knox AJ: Effect of antibiotic treatment on inflammatory markers and lung function in cystic fibrosis patients with Pseudomonas cepacia. Thorax 1994, 49(8):803-807.
• [24]Sequeiros IM, Jarad NA: Extending the course of intravenous antibiotics in adult patients with cystic fibrosis with acute pulmonary exacerbations. Chron Respir Dis 2012, 9(4):213-220.
• [25]Gray RD, Imrie M, Boyd AC, Porteous D, Innes JA, Greening AP: Sputum and serum calprotectin are useful biomarkers during CF exacerbation. J Cyst Fibros 2010, 9(3):193-198.
• [26]Sequeiros IM, Jarad N: Factors associated with a shorter time until the next pulmonary exacerbation in adult patients with cystic fibrosis. Chron Respir Dis 2012, 9(1):9-16.
• [27]Nixon LS, Yung B, Bell SC, Elborn JS, Shale DJ: Circulating immunoreactive interleukin-6 in cystic fibrosis. Am J Respir Crit Care Med 1998, 157(6 Pt 1):1764-1769.
• [28]Elborn JS, Cordon SM, Parker D, Delamere FM, Shale DJ: The host inflammatory response prior to death in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection. Respir Med 1993, 87(8):603-607.
• [29]Valletta EA, Rigo A, Bonazzi L, Zanolla L, Mastella G: Modification of some markers of inflammation during treatment for acute respiratory exacerbation in cystic fibrosis. Acta Paediatr 1992, 81(3):227-230.
• [30]Duggan C, Colin AA, Agil A, Higgins L, Rifai N: Vitamin A status in acute exacerbations of cystic fibrosis. Am J Clin Nutr 1996, 64(4):635-639.
• [31]Bell SC, Bowerman AM, Nixon LE, Macdonald IA, Elborn JS, Shale DJ: Metabolic and inflammatory responses to pulmonary exacerbation in adults with cystic fibrosis. Eur J Clin Invest 2000, 30(6):553-559.
• [32]Stevens DA, Moss RB, Kurup VP, Knutsen AP, Greenberger P, Judson MA, Denning DW, Crameri R, Brody AS, Light M, Skov M, Maish W, Mastella G, participants in the Cystic Fibrosis Foundation Consensus Conference: Allergic bronchopulmonary aspergillosis in cystic fibrosis. State of the Art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003, 37 Suppl 3:S 225-64.
• [33]Ibrahim M, Elborn J, Rendall J, Parkins M: Clinical features and outcomes of cystic fibrosis pulmonary exacerbations presenting with normal inflammatory markers. In Journal of Cystic Fibrosis. Oxford, UK: Elsevier; 2010:S56.
• [34]Pepys MB, Hirschfield GM: C-reactive protein: a critical update. J Clin Invest 2003, 111(12):1805-1812.
• [35]Zemanick ET, Harris JK, Wagner BD, Robertson CE, Sagel SD, Stevens MJ, Accurso FJ, Laguna TA: Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations. PLoS One 2013 Apr 30, 8(4):e62917.
• [36]Cantón R, Cobos N, de Gracia J, Baquero F, Honorato J, Gartner S: Tratamiento antimicrobiano frente a la colonización pulmonar por Pseudomonas aeruginosa en el paciente con fibrosis quística. Arch Bronconeumol 2005, 41(Supl 1):1-25.
• [37]Downey DG, Brockbank S, Martin SL, Ennis M, Elborn JS: The effect of treatment of cystic fibrosis pulmonary exacerbations on airways and systemic inflammation. Pediatr Pulmonol 2007, 42:729-735.
• [38]Martin SL, Moffitt KL, McDowell A, Greenan C, Bright-Thomas RJ, Jones AM, Webb AK, Elborn JS: Association of airway cathepsin B and S with inflammation in cystic fibrosis. Pediatr Pulmonol 2010 Sep, 45(9):860-68.